Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
Introduction
Allergic rhinitis (AR) represents a global health care problem that greatly affects daily activity, work productivity, learning, sleep, and quality of life (QOL) in people of all ages [1]. Japanese cedar pollinosis (JCP) is a unique allergic disease not seen outside of Japan. A massive amount of pollen is dispersed in the spring. The disease affects many people in cities far from the source of the pollen because pollen travels long distances. The disease has high morbidity (35%) in the adult Japanese population and the prevalence of JCP is increasing [1], [2].
Allergen-specific immunotherapy (IT) is recognized as the only curable treatment for AR. Subcutaneous immunotherapy (SCIT) has been used for treating AR in Japan. However, SCIT has several drawbacks such as the requirement for frequent hospital visits, injection site pain, and the risk of rare serious adverse drug reactions such as anaphylaxis [3]. Sublingual immunotherapy (SLIT) was developed to overcome these drawbacks and can be administered at home under a physician's direction. However, SLIT should be started after a correct diagnosis of AR and administered by the appropriate method [4], [5].
Clinical trials have demonstrated the effectiveness of SLIT for patients with JCP [6], [7]. National health insurance in Japan has covered SLIT for JCP since October 2014 and for house dust mite (HDM) since 2015. Based on research by the Japanese Rhinologic Society (JRS), the present guideline was prepared to provide accurate knowledge of SLIT and to contribute to the development of this therapy [8]. The JRS is an independent academic organization that receives no sponsorship or funding from specific organizations or businesses. Furthermore, the JRS has not obtained funds for the preparation of the present guidelines from any businesses, which include businesses representing the pharmaceutical industry.
Section snippets
Criteria for determining recommendation grades
This article discusses some clinical questions (CQs). Clinical questions were prepared with regard to the procedures, effects, adverse reactions, and mechanisms of SLIT. The literature published between January 2003 and December 2012 was searched for evidence using the databases of PubMed, the Cochrane Library, and the Japan Medical Abstracts Society (Web version 4). The principal search period was between October 2012 and June 2013 and the main search terms were “allergic rhinitis”,
CQ1: does SLIT improve symptoms and QOL in patients with seasonal allergic rhinitis?
A meta-analysis of randomized placebo-controlled double-blind trials (RCTs) on the use of SLIT for seasonal allergic rhinitis (SAR) demonstrated that symptom scores and medication scores improved significantly in the active treatment group (Level Ia) [9], the symptoms of the active treatment group improved in all trials, and a significant effect was observed in 21 (58%) of 36 trials (Level Ia) [10], and that high efficacy rates were observed in adults and in patients who received preseason
Conflicts of interest
Organizations or businesses that have provided research funding (for contract research, joint research, clinical trials, etc.), scholarship donations, and monetary compensations for lectures, manuscripts, and pamphlets to members of the guideline preparation committee are the following (the period of interest is between January 2012 and December 2013): Astellas Pharma, Inc. (Tokyo, Japan), AstraZeneca K.K. (Osaka, Japan), Bayer Yakuhin, Ltd. (Osaka, Japan), Chugai Pharmaceutical Co., Ltd.
References (86)
- et al.
Guiding principles of subcutaneous immunotherapy for allergic rhinitis in Japan
Aurus Nasus Larynx
(2014) - et al.
Examination, diagnosis and classification for Japanese allergic rhinitis: Japanese guideline
Auris Nasus Larynx
(2012) - et al.
Japanese guideline for allergic rhinitis 2014
Allergol Int
(2014) - et al.
A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis
Allergol Int
(2008) - et al.
Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systemic review and meta-analysis
J Allergy Clin Immunol
(2010) - et al.
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials
Ann Allergy Asthma Immunol
(2006) - et al.
Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis
J Allergy Clin Immunol
(2004) - et al.
Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis
J Allergy Clin Immunol
(2004) - et al.
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study
Ann Allergy Asthma Immunol
(2008) - et al.
Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study
J Allergy Clin Immunol
(2010)
Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study
J Allergy Clin Immunol
Oral allergy syndrome: a clinical, diagnostic, and therapeutic challenge
Ann Allergy Asthma Immunol
Update on sublingual immunotherapy
Ann Allergy Asthma Immunol
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis
J Allergy Clin Immunol
Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis
J Allergy Clin Immunol
Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy
Allergol Immunopathol
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis
J Allergy Clin Immunol
Sublingual immunotherapy: a comprehensive review
J Allergy Clin Immunol
Evidence-based practice: sublingual immunotherapy for allergic rhinitis
Otolaryngol Clin North Am
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language
J Allergy Clin Immunol
Appropriate and inappropriate use of immunotherapy
Ann Allergy Asthma Immunol
The immune privilege of the oral mucosa
Trends Mol Med
Characterization of dendritic cells from human oral mucosa: a new Langerhans’ cell type with high constitutive FcepsilonRI expression
J Allergy Clin Immunol
Regulatory T cells and immune tolerance
Cell
Induced regulatory T cells: mechanisms of conversion and suppressive potential
Hum Immunol
CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction
Immunity
Sublingual immunotherapy may affect serum neopterin: preliminary findings
Int Immunopharmacol
Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B-C serum levels in patients with allergic rhinitis
Int Immunopharmacol
Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis
Clin Immunol
Present state of Japanese cedar pollinosis: the national affliction
J Allergy Clin Immunol
Prevalence of allergic rhinitis and sensitization to common aeroallergens in a Japanese population
Int Arch Allergy Immunol
A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis
Int Arch Allergy Immunol
A guide to sublingual immunotherapy for allergic rhinitis
Jpn J Rhinol
Systematic review of sublingual immunotherapy (SLIT)
Allergy
Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma
JAMA
Antigen specific sublingual immunotherapy for pediatric Japanese cedar pollinosis
Arerugi
Sublingual immunotherapy for allergic rhinitis
Cochrane Database Syst Rev
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis
Allergy
House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis
Clin Exp Allergy
Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis
Laryngoscope
Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of pediatric literature
Arch Dis Child
Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012
Ann Allergy Asthma Immunol
Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial
Clin Exp Allergy
Cited by (17)
Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report
2020, Journal of Allergy and Clinical Immunology: In PracticeCompromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines
2020, World Allergy Organization JournalCitation Excerpt :Then, in source Table 2 the evidence was fused, and a proposed recommendation for GUIMIT 2019 was formulated (for links to all source documents available in ResearchGate, see addendum 1 GUIMIT 2019-online). For some chapters, guidance from the main reference guidelines was missing and some chapter-specific reference guidelines had to be added,13–19 following the same selection strategy using AGREE-II to sort out the best ones available. However, the main reference guidelines, some reflecting the European school7,8,16 and some the US school,11,15 did not agree on several issues as the practice of AIT in both schools differs.
Current status of sublingual immunotherapy for allergic rhinitis in Japan
2018, Allergology InternationalCitation Excerpt :Furthermore, as its drug adverse reactions are mild compared with SCIT, it is easy to introduce SLIT. However, before introducing SLIT, a correct diagnosis of JCP-or HDM-induced AR is necessary, and the appropriate indication for SLIT must be considered carefully.21 Adequate informed consent from patients with regard to the administration schedule of SLIT and local AE frequently observed during the early time of the introduction of SLIT is also required.
Evaluation of the quality of guidelines for sublingual immunotherapy of allergic rhinitis
2023, European Archives of Oto-Rhino-Laryngology